Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.
AuthorsStewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B
JournalMol Cell Proteomics
PubMed ID16319398
Nearly all women diagnosed with ovarian cancer receive combination chemotherapy including cis- or carboplatin. Despite high initial response rates, resistance to cisplatin develops in roughly one-third of women during primary treatment and in all women treated for recurrent disease. ICAT coupled with tandem MS is a quantitative proteomic technique for ... More